Skip to main content
EDAP
NASDAQ Life Sciences

EDAP TMS Reports Flat $70.5M Revenue, $(0.78) Annual Loss Per Share

feedReported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$3.75
Mkt Cap
$146.203M
52W Low
$1.21
52W High
$5.05
Market data snapshot near publication time

summarizeSummary

EDAP TMS SA filed its 10-K, reporting fiscal year revenue of $70.5 million, which was essentially flat year-over-year, and a basic loss per share of $(0.78). This detailed financial disclosure follows an earlier 8-K filing today that highlighted strong Q4 and full-year HIFU business growth. Despite the operational growth, the overall financial results show a significant net loss of $29.2 million. The company also noted $20.45 million in cash and cash equivalents, with an expected Tranche B draw to support operations for at least 12 months, indicating a reliance on future financing. This flat revenue and substantial loss are material for a company of EDAP's market capitalization, and traders will be watching for updates on the expected financing and the company's ability to achieve its projected revenue expansion and margin improvement.

At the time of this announcement, EDAP was trading at $3.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.2M. The 52-week trading range was $1.21 to $5.05. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


show_chartPrice Chart

Share this article

Copied!

feed EDAP - Latest Insights

EDAP
Apr 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
EDAP
Mar 25, 2026, 4:25 PM EDT
Filing Type: S-3
Importance Score:
9
EDAP
Mar 25, 2026, 4:25 PM EDT
Source: Wiseek News
Importance Score:
8
EDAP
Mar 25, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
9
EDAP
Mar 25, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
EDAP
Feb 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
EDAP
Jan 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8